Autolus Therapeutics plc (NASDAQ:AUTL) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) have been given an average recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.52.

A number of equities research analysts recently issued reports on AUTL shares. Wells Fargo & Company dropped their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP increased its stake in shares of Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after buying an additional 1,125,454 shares during the period. FMR LLC raised its holdings in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after purchasing an additional 5,478,706 shares during the last quarter. TFG Asset Management GP Ltd raised its holdings in Autolus Therapeutics by 3.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company’s stock worth $19,388,000 after purchasing an additional 250,000 shares during the last quarter. Candriam S.C.A. acquired a new position in Autolus Therapeutics during the 4th quarter valued at about $7,500,000. Finally, AXA S.A. bought a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $4,288,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Stock Performance

NASDAQ AUTL traded up $0.03 during trading on Friday, reaching $1.70. 1,642,224 shares of the company traded hands, compared to its average volume of 1,375,171. Autolus Therapeutics has a 1-year low of $1.57 and a 1-year high of $6.60. The stock’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $2.93. The company has a market cap of $452.36 million, a price-to-earnings ratio of -1.40 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. Equities research analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.